The global urinary tract cancer market was valued at $1,704.5 million in 2020, and is estimated to reach $8,786.2 million by 2030, growing at a CAGR of 18.6% from 2021 to 2030.
Urinary tract cancer is defined as the type of cancer, which develop a lesion ranging from small benign tumors to aggressive neoplasm with high mortality. The urinary tract cancer is found in the bladder, ureters, renal pelvis, and urethra. The most common urinary tract cancer is bladder cancer. The sign and symptoms of urinary tract cancer are blood clots in the urine, frequent urination, and back pain.
The global urinary tract cancer market is majorly driven by an alarming increase in the prevalence of bladder cancer, a rise in government initiative for prevention and treatment of bladder cancer, availability of advanced therapy, increase in number of approval of drugs, and rise in funds for R&D activities. For instance, according to the American Cancer Society, in 2021, approximately 17,200 deaths were reported due to bladder cancer, in the U.S., and around 83,730 population are diagnosed with this disease. Bladder cancer is the tenth most common cancer, across the globe. Moreover, in January 2021, the European Commission announced the approval of Bavencio (avelumab), which is used for the treatment of locally advanced or metastatic urothelial carcinoma. Furthermore, in 2020, Bristol Myers Squibb, a global pharmaceutical company, spends $11.1 billion in R&D activities. In addition, the rise in the geriatric population, who are more vulnerable to urinary tract cancer, drive the growth of the market. Further, increase in need for available biologic therapy and rise in prevalence of urinary tract cancer are expected to propel the growth of the market.
Increase in number of R&D activities and advancement in healthcare services are the major factors that drive the global urinary tract cancer market. Moreover, increase in sedentary lifestyle significantly contributes toward the market growth, owing to the fact that smoker, and alcohol consumers are more susceptible to bladder cancer. According to the National Institute of Health (NIH), in 2018, it was observed that around 50% of all the case of bladder cancer are diagnosed in smokers. Rise in demand for early diagnosis of disease for effective treatment acts a key driving force of the global market. Furthermore, governments are taking multiple initiatives to support healthcare infrastructure and increase the healthcare spending, which is expected to boost the market growth. According to Centers for Medicare & Medicaid Services (CMC), in 2019, it was reported that the U.S. health care spending increased by 4.6% to reach $3.8 trillion, or $11,582 per person. It allows the healthcare organization to develop and produce advanced therapy for the treatment of urinary tract cancer. In addition, increase in number of bladder cancer research centers is anticipated to provide lucrative opportunities for the market expansion. For instance, in November 2020, the University of Birmingham, in the UK, announced the launch of bladder cancer research centers, which aims to translate biomedical science into healthcare benefits for patients suffering from bladder cancer. A combination of University investment and philanthropic donation funded $1.23 million for the development of bladder cancer research centers.
On the contrary, risk associated with the use of drugs for treatment of bladder cancer such as irritation in bladder, blood in urine, and infection is anticipated to hinder the market growth during the forecast period. The rise in health reimbursement and presence of highly specialized urologist for cancer treatment leads to the enhancement of the urinary tract cancer sector. This encourages many key players to enter emerging markets, thus offering a lucrative growth opportunity in the urinary tract cancer market.
The global urinary tract cancer market is segmented into cancer type, treatment type, distribution channel, and region. By cancer type, the market is categorized into bladder cancer, urethral cancer, and ureteric and renal pelvic cancer.
By treatment type, it is divided into chemotherapy, and immunotherapy. By distribution channel, the market is bifurcated into retail pharmacy, and online pharmacy. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global urinary tract cancer market are Astellas Pharma Inc., Bristol-Myers Squibb Company, Eli Lily and Company, Endo International plc., Exelixis, Inc., GlaxoSmithKline Plc.(GSK), Merck KGAA, Novartis AG, Pfizer Inc., and Johnson & Johnson.
Urinary tract cancer is defined as the type of cancer, which develop a lesion ranging from small benign tumors to aggressive neoplasm with high mortality. The urinary tract cancer is found in the bladder, ureters, renal pelvis, and urethra. The most common urinary tract cancer is bladder cancer. The sign and symptoms of urinary tract cancer are blood clots in the urine, frequent urination, and back pain.
The global urinary tract cancer market is majorly driven by an alarming increase in the prevalence of bladder cancer, a rise in government initiative for prevention and treatment of bladder cancer, availability of advanced therapy, increase in number of approval of drugs, and rise in funds for R&D activities. For instance, according to the American Cancer Society, in 2021, approximately 17,200 deaths were reported due to bladder cancer, in the U.S., and around 83,730 population are diagnosed with this disease. Bladder cancer is the tenth most common cancer, across the globe. Moreover, in January 2021, the European Commission announced the approval of Bavencio (avelumab), which is used for the treatment of locally advanced or metastatic urothelial carcinoma. Furthermore, in 2020, Bristol Myers Squibb, a global pharmaceutical company, spends $11.1 billion in R&D activities. In addition, the rise in the geriatric population, who are more vulnerable to urinary tract cancer, drive the growth of the market. Further, increase in need for available biologic therapy and rise in prevalence of urinary tract cancer are expected to propel the growth of the market.
Increase in number of R&D activities and advancement in healthcare services are the major factors that drive the global urinary tract cancer market. Moreover, increase in sedentary lifestyle significantly contributes toward the market growth, owing to the fact that smoker, and alcohol consumers are more susceptible to bladder cancer. According to the National Institute of Health (NIH), in 2018, it was observed that around 50% of all the case of bladder cancer are diagnosed in smokers. Rise in demand for early diagnosis of disease for effective treatment acts a key driving force of the global market. Furthermore, governments are taking multiple initiatives to support healthcare infrastructure and increase the healthcare spending, which is expected to boost the market growth. According to Centers for Medicare & Medicaid Services (CMC), in 2019, it was reported that the U.S. health care spending increased by 4.6% to reach $3.8 trillion, or $11,582 per person. It allows the healthcare organization to develop and produce advanced therapy for the treatment of urinary tract cancer. In addition, increase in number of bladder cancer research centers is anticipated to provide lucrative opportunities for the market expansion. For instance, in November 2020, the University of Birmingham, in the UK, announced the launch of bladder cancer research centers, which aims to translate biomedical science into healthcare benefits for patients suffering from bladder cancer. A combination of University investment and philanthropic donation funded $1.23 million for the development of bladder cancer research centers.
On the contrary, risk associated with the use of drugs for treatment of bladder cancer such as irritation in bladder, blood in urine, and infection is anticipated to hinder the market growth during the forecast period. The rise in health reimbursement and presence of highly specialized urologist for cancer treatment leads to the enhancement of the urinary tract cancer sector. This encourages many key players to enter emerging markets, thus offering a lucrative growth opportunity in the urinary tract cancer market.
The global urinary tract cancer market is segmented into cancer type, treatment type, distribution channel, and region. By cancer type, the market is categorized into bladder cancer, urethral cancer, and ureteric and renal pelvic cancer.
By treatment type, it is divided into chemotherapy, and immunotherapy. By distribution channel, the market is bifurcated into retail pharmacy, and online pharmacy. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global urinary tract cancer market are Astellas Pharma Inc., Bristol-Myers Squibb Company, Eli Lily and Company, Endo International plc., Exelixis, Inc., GlaxoSmithKline Plc.(GSK), Merck KGAA, Novartis AG, Pfizer Inc., and Johnson & Johnson.
KEY BENEFITS FOR STAKEHOLDERS
- The report provides an in-depth analysis of the global urinary tract cancer market size along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
- A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global urinary tract cancer market.
KEY MARKET SEGMENTS
By Cancer type
- Bladder Cancer
- Urethral cancer
- Ureteric and Renal Pelvic Cancer
By Treatment Type
- Chemotherapy
- Retail Pharmacy
- Online Pharmacy
- Immunotherapy
- Retail Pharmacy
- Online Pharmacy
By Distribution Channel
- Retail Pharmacy
- Online Pharmacy
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
KEY MARKET PLAYERS
- Astellas Pharma Inc.
- Bristol-Myers Squibb Company
- Eli Lily and Company
- Endo International plc.
- Exelixis, Inc.
- GlaxoSmithKline Plc. (GSK)
- Merck KGAA
- Novartis AG
- Pfizer Inc.
- Johnson & Johnson
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET LANDSCAPE
CHAPTER 4: URINARY TRACT CANCER MARKET, BY CANCER TYPE
CHAPTER 5: URINARY TRACT CANCER MARKET, BY TREATMENT TYPE
CHAPTER 6: URINARY TRACT CANCER MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: URINARY TRACT CANCER MARKET, BY REGION
CHAPTER 8: COMPANY PROFILES
List of Tables
List of Figures
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 249 |
| Published | September 2021 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 1704.5 million |
| Forecasted Market Value ( USD | $ 8786.2 million |
| Compound Annual Growth Rate | 17.8% |
| Regions Covered | Global |
